The burden of respiratory syncytial virus in children under 5 years of age in Norway
- PMID: 34906596
- DOI: 10.1016/j.jinf.2021.12.008
The burden of respiratory syncytial virus in children under 5 years of age in Norway
Erratum in
-
Corrigendum to 'The burden of respiratory syncytial virus in children under 5 years of age in Norway' [Journal of Infection Volume 84, Issue 2 (2022) Pages 205-215].J Infect. 2023 Apr;86(4):420. doi: 10.1016/j.jinf.2022.12.018. Epub 2022 Dec 24. J Infect. 2023. PMID: 36572618 No abstract available.
Abstract
Objectives: To estimate age-specific incidence of medically attended respiratory syncytial virus (RSV) infections in hospitalised Norwegian children and describe disease epidemiology.
Methods: Active prospective hospital surveillance for RSV in children <59 months of age was conducted during 2015-2018. All febrile children 12-59 months of age were enrolled, whereas children <12 months were enrolled based on respiratory symptoms regardless of fever. Surveillance data were linked to national registry data to estimate the clinical burden of RSV.
Results: Of the children enrolled, 1096 (40%) were infected with RSV. The highest incidence rates were found in children 1 month of age, with a peak incidence of 43 per 1000 during the 2016-2017 season. In comparison, children 24-59 months of age had an infection rate of 1.4 per 1000 during the same winter season. The peak season was during the 2016-2017 winter, with an incidence rate of 6.0 per 1000 children 0-59 months of age. In the study population a total of 168 (15%) of the infected children had pre-existing medical conditions predisposing for more severe disease. High infection rates were found in this population.
Conclusions: Children with comorbidities showed high hospital contact rates, but the majority of children in need of medical attention associated with RSV infection were previously healthy.
Keywords: Children; Disease burden; RSV; Respiratory syncytial virus; Surveillance.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Elmira Flem is currently employed by Merck Sharp & Dohme Corp., Drammen, Norway, a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey. The work for the current study was conducted by Dr. Flem under the previous affiliation. The author(s) hereby declare that no other conflicts of interest exist.
Comment in
-
Microorganisms in patients with acute respiratory tract infections in Bamako, Mali.J Infect. 2022 Oct;85(4):e83-e85. doi: 10.1016/j.jinf.2022.07.012. Epub 2022 Jul 22. J Infect. 2022. PMID: 35878685 No abstract available.